Ablynx Overview

  • Founded

  • 2001

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 438

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $4.72B

Ablynx General Information

Description

Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, hematology, immuno-oncology, oncology and respiratory diseases. The company's biopharmaceutical products comprises of their patented product named, Nanobodies that is a therapeutic proteins based on single-chain antibody fragments that combine the benefits of drugs based on conventional antibodies and small chemical molecules, enabling patients avail various therapeutic and new drugs that can make a clear difference to society.

Contact Information

Website
www.ablynx.com
Formerly Known As
MatchX
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Sanofi
Primary Office
  • Technologiepark 21
  • 9052 Ghent
  • Belgium

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ablynx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Merger/Acquisition 14-May-2018 $4.72B 00000 00.000 Completed Profitable
13. Merger/Acquisition 01-Dec-2017 00.000 00.000 Cancelled Profitable
12. 2PO 25-Oct-2017 00000 00000 00.00 Completed Profitable
11. PIPE 04-Oct-2017 00000 Completed Profitable
10. Secondary Transaction - Open Market 03-Nov-2016 00000 Completed Profitable
9. PIPE 01-Jun-2016 000.00 00000 Completed Profitable
8. Secondary Transaction - Open Market 18-Oct-2013 00.000 00000 Completed Generating Revenue
7. 2PO 16-Mar-2010 000.00 00000 Completed Generating Revenue
6. IPO 07-Nov-2007 $108M $196M Completed Generating Revenue
5. Later Stage VC (Series C) 23-Aug-2006 $51.2M $88.2M Completed Generating Revenue
To view Ablynx’s complete valuation and funding history, request access »

Ablynx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, h
Biotechnology
Ghent, Belgium
438 As of 2017
00000
0.000 0000-00-00
000000&0 00000

000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupid
0000000000000
Pasadena, CA
000 As of 0000
00.000
000000 - 000 00.000

00000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut eni
0000 000000000
Pasadena, CA
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ablynx Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
00000 000000000000 Corporation Pasadena, CA 0 000.00 000000000 000.00
000 000000000000 Formerly PE-Backed High Point, NC 00 00000 000000000
00000 Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
000000000 00000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 0000000000 0 00000
You’re viewing 5 of 52 competitors. Get the full list »

Ablynx Patents

  • 1,096

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 87

    Granted

  • 8

    Pending

  • 000

    Expiring in next 12 mo

Ablynx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4126971-A1 Method for the production and purification of multivalent immunoglobulin single variable domains Pending 30-Mar-2020 000000000
AU-2021246890-A1 Method for the production and purification of multivalent immunoglobulin single variable domains Pending 30-Mar-2020 000000000
CA-3175873-A1 Method for the production and purification of multivalent immunoglobulin single variable domains Pending 30-Mar-2020 000000000
EP-3636657-A1 Chromatography-free antibody purification method Inactive 08-Oct-2018 00000000 00
US-20210371457-A1 Chromatography-free antibody purification method Pending 08-Oct-2018 C07K1/34
To view Ablynx’s complete patent history, request access »

Ablynx Board Members (10)

Name Representing Role Since
Bo Jesper Hansen Ph.D Self Board Member 000 0000
You’re viewing 1 of 10 board members. Get the full list »

Ablynx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ablynx Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Venture Capital Minority 000 0000 000000 0
Alta Partners Venture Capital Minority 000 0000 000000 0
Fidelity Management & Research Venture Capital Minority 000 0000 000000 0
Gilde Healthcare Venture Capital Minority 000 0000 000000 0
Gimv PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial